

Human AGER Protein

Cat. No. AER-HM101



Description

Source	Recombinant Human AGER Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Ala23- Ala344.
Accession	Q15109-1
Molecular Weight	The protein has a predicted MW of 35.3 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per µg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE > 95% as determined by HPLC

Formulation and Storage

Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt. -20 to -80°C for 3-6 months in unopened state after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

The receptor for advanced glycation end products (AGER) is an oncogenic transmembranous receptor up-regulated in various human cancers. AGER promotes proliferation, migration, and inhibits apoptosis of squamous cervical cancer and might function as a tumor promoter in cervical cancer. Our study provides novel evidence for a potential role of AGER in bridging human papillomavirus (HPV)-induced inflammation and cervical cancer.

Assay Data


Tris-Bis PAGE



Human AGER on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Assay Data



The purity of Human AGER is greater than 95% as determined by SEC-HPLC.